CSIMarket
 
Novavax inc   (NVAX)
Other Ticker:  
 
 
Price: $15.5000 $0.35 2.310%
Day's High: $15.96 Week Perf: 4.8 %
Day's Low: $ 14.96 30 Day Perf: 292.41 %
Volume (M): 12,750 52 Wk High: $ 17.40
Volume (M$): $ 197,617 52 Wk Avg: $6.51
Open: $15.47 52 Wk Low: $3.53



 Market Capitalization (Millions $) 2,169
 Shares Outstanding (Millions) 140
 Employees 370
 Revenues (TTM) (Millions $) 997
 Net Income (TTM) (Millions $) -399
 Cash Flow (TTM) (Millions $) -141
 Capital Exp. (TTM) (Millions $) 43

Novavax Inc
Novavax Inc.
is a clinical-stage biotechnology company that specializes in the development of vaccines to prevent infectious diseases.
The company is headquartered in Gaithersburg, Maryland, and was founded in 1987.
Novavax's focus is on developing novel recombinant protein nanoparticle vaccines using its proprietary technology platform, Matrix-M.
Matrix-M is a proprietary saponin adjuvant that stimulates the immune system and enhances the efficacy of vaccines.
Novavax has used this adjuvant to develop vaccines for a variety of infectious diseases, including influenza, respiratory syncytial virus (RSV), COVID-19, and Ebola.
Novavax's lead product candidate, NVX-CoV2373, is a COVID-19 vaccine that uses Matrix-M to enhance the immune response to the SARS-CoV-2 spike protein.
The vaccine is administered in two doses, 21 days apart, and has shown high levels of efficacy in clinical trials conducted in the UK and South Africa.
Novavax has partnered with several organizations to develop and distribute its vaccines globally.
In the US, the company has received funding from the US Department of Defense, the National Institutes of Health, and the Coalition for Epidemic Preparedness Innovations (CEPI).
Overall, Novavax Inc is a biotechnology company that is pioneering the use of recombinant protein nanoparticle vaccines, with its proprietary Matrix-M technology.
The company has a strong pipeline of vaccines and partnerships with several organizations for global distribution.


   Company Address: 700 Quince Orchard Road, Gaithersburg, 20878
   Company Phone Number: 268-2000   Stock Exchange / Ticker: NASDAQ NVAX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Novavax Inc

2. A Closer Look at Novavax Inc's Financial Success in Q1 2024

Novavax Inc, a biotechnology and pharmaceutical company, has shown promising results in its fiscal interval ending March 31, 2024. The company's loss per share decreased significantly from $-3.41 to $-1.05 in comparison to the previous year. This improvement in earnings per share indicates a positive trend in the company's financial performance.
Moreover, Novavax Inc has also experienced a noteworthy increase in revenue during this period. The revenue grew by an impressive 15.941%, reaching $93.86 million as compared to $80.95 million in the same reporting period a year before. However, it is important to note that the revenue sequentially tumbled by -67.785% from $291.34 million.

Novavax Inc

Novavax Inc. Struggles in the Face of Steep Revenue Decline of -18.483%

Novavax Inc, a biotechnology and pharmaceutical company, has recently reported its financial results for the most recent fiscal period, and things are not looking good for the company. Despite a slight improvement in its loss per share compared to the previous year, Novavax still reported a significant shortfall of $-1.33 per share. Additionally, the company saw a substantial decline in revenue, with a decrease of -18.483% to $291.34 million from the same period a year prior.
One promising sign is that Novavax did manage to reduce its net deficit slightly from the previous reporting period, but the overall financial picture remains bleak. The company reported a net deficit of $-178.389 million in the most recent fiscal period, and has a net deficit of $-545.06 million for the financial year 2023.

Novavax Inc

Novavax Inc gears up for a crucial Q3 earnings season in 2023

Novavax Inc, a biotechnology and pharmaceutical company, experienced a decline in financial performance for the fiscal period of July to September 2023. The company reported a loss of $-1.26 per share, an improvement from a loss of $-2.15 per share in the same period last year. Earnings per share also decreased from $0.58 per share in the previous financial reporting period.
The revenue for Novavax Inc dropped sharply by -74.545% to $186.99 million compared to $734.58 million in the corresponding period a year ago. Sequentially, the revenue tumbled by -55.944% from $424.43 million. This significant decline indicates a challenging period for the company in terms of generating revenue.

Novavax Inc

Novavax Inc witnesses remarkable surge in revenue, but EPS succumbs amidst fiscal period ending June 30, 2023



Novavax Inc, a leading biotechnology and pharmaceuticals company, has recently released its financial results for the second quarter of 2023. The company showcased remarkable growth, with a 128.278% increase in revenue and a turnaround to profitability, accompanied by positive Income per Share (EPS). This article will analyze the impact of these results on Novavax's future prospects and the overall biotechnology and pharmaceuticals sector.
1. Enhanced Profits:
Novavax's Q2 2023 financial report revealed a significant improvement in profitability. Despite facing obstacles in the sector, the company managed to generate a net income of $58.008 million, marking a remarkable improvement compared to a net loss of $-510.485 million in the same period the previous year. This shift is indicative of a successful turnaround strategy implemented by Novavax, positioning them competitively within the market.

Novavax Inc

Novavax Inc's Challenging Fiscal Q1 2023: $1 Billion Net Loss Results in Negative ROI of -945.37%

Novavax Inc Posts Negative ROI of -945.37% Due to $1 Billion Net Loss in First Quarter of 2023
In a recent financial report,
Novavax Inc, a healthcare company, revealed a negative return on investment (ROI) of -945.37%, primarily due to a significant net loss of $-1 billion in the first quarter of 2023. This performance puts Novavax Inc behind 523 other companies operating within the Healthcare sector that fared better in terms of ROI.
However, despite the negative ROI, the company's ranking based on ROI improved in the first quarter of 2023, moving up from 4964 in the Q4 2022 to 2903 in Q1 of 2023.






 

Novavax Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Novavax Inc does not provide revenue guidance.

Earnings Outlook
Novavax inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com